Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.50 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.46 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14821040 | 1.00 | SSTR3 (0.55) | SSTR3SIRT2SIRT1CALCRLECE1 | |
| SCHEMBL17706674 | 1.00 | SSTR3 (0.55) | SSTR3SIRT2SIRT1CALCRLECE1 | |
| SCHEMBL14872058 | 0.93 | SSTR3 (0.55) | SSTR3SIRT2SIRT1CALCRLECE1 | |
| SCHEMBL19403504 | 0.91 | SSTR3 (0.54) | SSTR3SIRT2SIRT1CALCRLECE1 | |
| SCHEMBL12245289 | 0.88 | SSTR3 (0.53) | SSTR3SIRT2SIRT1CALCRLECE1 | |
| SCHEMBL16479322 | 0.87 | SSTR3 (0.53) | SSTR3SIRT2SIRT1CALCRLLTA4H | |
| SCHEMBL22096459 | 0.87 | SSTR3 (0.51) | SSTR3SIRT2SIRT1CALCRLLTA4H | |
| SCHEMBL24101424 | 0.86 | SSTR3 (0.54) | SSTR3CALCRLLTA4HMMP3KDM1A | |
| SCHEMBL13684815 | 0.86 | SSTR3 (0.56) | SSTR3CALCRLLTA4HMMP3 | |
| SCHEMBL20420459 | 0.86 | CALCRL (0.56) | SSTR3CALCRLLTA4HMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021104834-A1 | COMBINATION THERAPY | ADC THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| EP-3338793-A1 | NOVEL SEZ6 MODULATORS AND METHODS OF USE | AbbVie Stemcentrx LLC (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2751076-B1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2018-04-25 | — | — | EP | disclosed |
| EP-2935268-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| WO-2017129652-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
| EP-2751111-B1 | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases | MEDIMMUNE LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| EP-2751110-B1 | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases | MEDIMMUNE LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| EP-2558445-B1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017020972-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | VAN BERKEL, Patricius Hendrikus Cornelis (CH) | 2017-02-09 | — | — | WO | disclosed |